Cargando…
PB2038: LENALIDOMIDE OR BORTEZOMIB AS MAINTENANCE TREATMENT OVERCOMES INFERIOR IMPACT OF HIGH-RISK CYTOGENETIC ABNORMALITIES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431666/ http://dx.doi.org/10.1097/01.HS9.0000850984.40192.e8 |
| _version_ | 1784780117676916736 |
|---|---|
| author | Zhuang, Z. Tian, Y. Shi, L. Zou, D. Feng, R. Tian, W.-W. Yu, H. Dong, F. Liao, A. Ma, Y. Liu, Q. Liu, S. Jing, H. Fu, R. Ma, L.-M. Liu, H. Sun, W. Bao, L. Wu, Y. Chen, W. Zhuang, J. |
| author_facet | Zhuang, Z. Tian, Y. Shi, L. Zou, D. Feng, R. Tian, W.-W. Yu, H. Dong, F. Liao, A. Ma, Y. Liu, Q. Liu, S. Jing, H. Fu, R. Ma, L.-M. Liu, H. Sun, W. Bao, L. Wu, Y. Chen, W. Zhuang, J. |
| author_sort | Zhuang, Z. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9431666 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94316662022-08-31 PB2038: LENALIDOMIDE OR BORTEZOMIB AS MAINTENANCE TREATMENT OVERCOMES INFERIOR IMPACT OF HIGH-RISK CYTOGENETIC ABNORMALITIES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA Zhuang, Z. Tian, Y. Shi, L. Zou, D. Feng, R. Tian, W.-W. Yu, H. Dong, F. Liao, A. Ma, Y. Liu, Q. Liu, S. Jing, H. Fu, R. Ma, L.-M. Liu, H. Sun, W. Bao, L. Wu, Y. Chen, W. Zhuang, J. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431666/ http://dx.doi.org/10.1097/01.HS9.0000850984.40192.e8 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Zhuang, Z. Tian, Y. Shi, L. Zou, D. Feng, R. Tian, W.-W. Yu, H. Dong, F. Liao, A. Ma, Y. Liu, Q. Liu, S. Jing, H. Fu, R. Ma, L.-M. Liu, H. Sun, W. Bao, L. Wu, Y. Chen, W. Zhuang, J. PB2038: LENALIDOMIDE OR BORTEZOMIB AS MAINTENANCE TREATMENT OVERCOMES INFERIOR IMPACT OF HIGH-RISK CYTOGENETIC ABNORMALITIES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA |
| title | PB2038: LENALIDOMIDE OR BORTEZOMIB AS MAINTENANCE TREATMENT OVERCOMES INFERIOR IMPACT OF HIGH-RISK CYTOGENETIC ABNORMALITIES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA |
| title_full | PB2038: LENALIDOMIDE OR BORTEZOMIB AS MAINTENANCE TREATMENT OVERCOMES INFERIOR IMPACT OF HIGH-RISK CYTOGENETIC ABNORMALITIES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA |
| title_fullStr | PB2038: LENALIDOMIDE OR BORTEZOMIB AS MAINTENANCE TREATMENT OVERCOMES INFERIOR IMPACT OF HIGH-RISK CYTOGENETIC ABNORMALITIES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA |
| title_full_unstemmed | PB2038: LENALIDOMIDE OR BORTEZOMIB AS MAINTENANCE TREATMENT OVERCOMES INFERIOR IMPACT OF HIGH-RISK CYTOGENETIC ABNORMALITIES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA |
| title_short | PB2038: LENALIDOMIDE OR BORTEZOMIB AS MAINTENANCE TREATMENT OVERCOMES INFERIOR IMPACT OF HIGH-RISK CYTOGENETIC ABNORMALITIES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA |
| title_sort | pb2038: lenalidomide or bortezomib as maintenance treatment overcomes inferior impact of high-risk cytogenetic abnormalities in transplant-ineligible patients with newly diagnosed multiple myeloma in china |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431666/ http://dx.doi.org/10.1097/01.HS9.0000850984.40192.e8 |
| work_keys_str_mv | AT zhuangz pb2038lenalidomideorbortezomibasmaintenancetreatmentovercomesinferiorimpactofhighriskcytogeneticabnormalitiesintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomainchina AT tiany pb2038lenalidomideorbortezomibasmaintenancetreatmentovercomesinferiorimpactofhighriskcytogeneticabnormalitiesintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomainchina AT shil pb2038lenalidomideorbortezomibasmaintenancetreatmentovercomesinferiorimpactofhighriskcytogeneticabnormalitiesintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomainchina AT zoud pb2038lenalidomideorbortezomibasmaintenancetreatmentovercomesinferiorimpactofhighriskcytogeneticabnormalitiesintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomainchina AT fengr pb2038lenalidomideorbortezomibasmaintenancetreatmentovercomesinferiorimpactofhighriskcytogeneticabnormalitiesintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomainchina AT tianww pb2038lenalidomideorbortezomibasmaintenancetreatmentovercomesinferiorimpactofhighriskcytogeneticabnormalitiesintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomainchina AT yuh pb2038lenalidomideorbortezomibasmaintenancetreatmentovercomesinferiorimpactofhighriskcytogeneticabnormalitiesintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomainchina AT dongf pb2038lenalidomideorbortezomibasmaintenancetreatmentovercomesinferiorimpactofhighriskcytogeneticabnormalitiesintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomainchina AT liaoa pb2038lenalidomideorbortezomibasmaintenancetreatmentovercomesinferiorimpactofhighriskcytogeneticabnormalitiesintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomainchina AT may pb2038lenalidomideorbortezomibasmaintenancetreatmentovercomesinferiorimpactofhighriskcytogeneticabnormalitiesintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomainchina AT liuq pb2038lenalidomideorbortezomibasmaintenancetreatmentovercomesinferiorimpactofhighriskcytogeneticabnormalitiesintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomainchina AT lius pb2038lenalidomideorbortezomibasmaintenancetreatmentovercomesinferiorimpactofhighriskcytogeneticabnormalitiesintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomainchina AT jingh pb2038lenalidomideorbortezomibasmaintenancetreatmentovercomesinferiorimpactofhighriskcytogeneticabnormalitiesintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomainchina AT fur pb2038lenalidomideorbortezomibasmaintenancetreatmentovercomesinferiorimpactofhighriskcytogeneticabnormalitiesintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomainchina AT malm pb2038lenalidomideorbortezomibasmaintenancetreatmentovercomesinferiorimpactofhighriskcytogeneticabnormalitiesintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomainchina AT liuh pb2038lenalidomideorbortezomibasmaintenancetreatmentovercomesinferiorimpactofhighriskcytogeneticabnormalitiesintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomainchina AT sunw pb2038lenalidomideorbortezomibasmaintenancetreatmentovercomesinferiorimpactofhighriskcytogeneticabnormalitiesintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomainchina AT baol pb2038lenalidomideorbortezomibasmaintenancetreatmentovercomesinferiorimpactofhighriskcytogeneticabnormalitiesintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomainchina AT wuy pb2038lenalidomideorbortezomibasmaintenancetreatmentovercomesinferiorimpactofhighriskcytogeneticabnormalitiesintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomainchina AT chenw pb2038lenalidomideorbortezomibasmaintenancetreatmentovercomesinferiorimpactofhighriskcytogeneticabnormalitiesintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomainchina AT zhuangj pb2038lenalidomideorbortezomibasmaintenancetreatmentovercomesinferiorimpactofhighriskcytogeneticabnormalitiesintransplantineligiblepatientswithnewlydiagnosedmultiplemyelomainchina |